Jazz Pharmaceuticals’ (JAZZ) Buy Rating Reaffirmed at Needham & Company LLC

Jazz Pharmaceuticals (NASDAQ:JAZZ)‘s stock had its “buy” rating reissued by analysts at Needham & Company LLC in a report released on Thursday, Benzinga reports. They currently have a $207.00 price objective on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price target suggests a potential upside of 85.57% from the stock’s previous close.

A number of other equities analysts have also commented on the company. Robert W. Baird reduced their price objective on Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating on the stock in a research note on Thursday, August 1st. Piper Sandler reduced their price target on shares of Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating on the stock in a research report on Thursday, August 1st. HC Wainwright restated a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, August 1st. JPMorgan Chase & Co. upped their target price on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a research report on Monday, August 19th. Finally, Royal Bank of Canada raised their price target on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an “outperform” rating in a report on Wednesday, October 23rd. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $173.57.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock opened at $111.55 on Thursday. The firm has a market capitalization of $6.89 billion, a P/E ratio of 19.17, a P/E/G ratio of 1.37 and a beta of 0.57. The stock has a fifty day moving average price of $110.42 and a two-hundred day moving average price of $109.61. Jazz Pharmaceuticals has a 52-week low of $99.06 and a 52-week high of $134.48. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 2.02.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Wednesday, November 6th. The specialty pharmaceutical company reported $5.86 earnings per share for the quarter, topping the consensus estimate of $4.54 by $1.32. The company had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.04 billion. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. As a group, analysts anticipate that Jazz Pharmaceuticals will post 16.02 EPS for the current fiscal year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the completion of the transaction, the chief executive officer now directly owns 428,976 shares in the company, valued at approximately $47,547,699.84. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the transaction, the senior vice president now owns 14,531 shares of the company’s stock, valued at approximately $1,573,707.30. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $110.84, for a total value of $110,840.00. Following the completion of the sale, the chief executive officer now owns 428,976 shares in the company, valued at approximately $47,547,699.84. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.20% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several large investors have recently made changes to their positions in the stock. Versant Capital Management Inc boosted its holdings in shares of Jazz Pharmaceuticals by 13,450.0% during the second quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after acquiring an additional 269 shares during the period. Itau Unibanco Holding S.A. bought a new position in Jazz Pharmaceuticals in the 2nd quarter valued at approximately $29,000. EverSource Wealth Advisors LLC lifted its holdings in Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 97 shares during the period. GAMMA Investing LLC boosted its stake in shares of Jazz Pharmaceuticals by 65.5% in the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 116 shares during the last quarter. Finally, Gladius Capital Management LP bought a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter valued at about $33,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.